Session

Hit the road JAK: Part 1

MAINTENANCE OF CLINICAL, ENDOSCOPIC, AND BIOMARKER IMPROVEMENTS WITH UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF THE PHASE 3 U-ENDURE STUDY
MAINTENANCE OF CLINICAL, ENDOSCOPIC, AND BIOMARKER IMPROVEMENTS WITH UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF THE PHASE 3 U-ENDURE STUDY

Hit the road JAK: Part 1  et al.

EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION AND MAINTENANCE THERAPY FOR CROHN’S DISEASE: RESULTS FROM THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DIVERSITY1 STUDY
EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION AND MAINTENANCE THERAPY FOR CROHN’S DISEASE: RESULTS FROM THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DIVERSITY1 STUDY

Hit the road JAK: Part 1  et al.

IMPACT OF RISANKIZUMAB ON INTESTINAL STENOSIS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: POST HOC ANALYSIS OF THE PHASE 3 ADVANCE, MOTIVATE, AND FORTIFY STUDIES
IMPACT OF RISANKIZUMAB ON INTESTINAL STENOSIS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: POST HOC ANALYSIS OF THE PHASE 3 ADVANCE, MOTIVATE, AND FORTIFY STUDIES

Hit the road JAK: Part 1  et al.

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 9.2 YEARS OF SAFETY DATA FROM THE GLOBAL CLINICAL PROGRAMME
TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 9.2 YEARS OF SAFETY DATA FROM THE GLOBAL CLINICAL PROGRAMME

Hit the road JAK: Part 1  et al.

RAPID CLINICAL RESPONSE TO UPADACITINIB THERAPY IS ASSOCIATED WITH IMPROVED CLINICAL AND ENDOSCOPIC OUTCOMES IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE
RAPID CLINICAL RESPONSE TO UPADACITINIB THERAPY IS ASSOCIATED WITH IMPROVED CLINICAL AND ENDOSCOPIC OUTCOMES IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE

Hit the road JAK: Part 1  et al.

IMPACT OF RISANKIZUMAB ON INTESTINAL STENOSIS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: POST HOC ANALYSIS OF THE PHASE 3 ADVANCE, MOTIVATE, AND FORTIFY STUDIES
IMPACT OF RISANKIZUMAB ON INTESTINAL STENOSIS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: POST HOC ANALYSIS OF THE PHASE 3 ADVANCE, MOTIVATE, AND FORTIFY STUDIES

MAINTENANCE OF CLINICAL, ENDOSCOPIC, AND BIOMARKER IMPROVEMENTS WITH UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF THE PHASE 3 U-ENDURE STUDY
MAINTENANCE OF CLINICAL, ENDOSCOPIC, AND BIOMARKER IMPROVEMENTS WITH UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF THE PHASE 3 U-ENDURE STUDY

RAPID CLINICAL RESPONSE TO UPADACITINIB THERAPY IS ASSOCIATED WITH IMPROVED CLINICAL AND ENDOSCOPIC OUTCOMES IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE
RAPID CLINICAL RESPONSE TO UPADACITINIB THERAPY IS ASSOCIATED WITH IMPROVED CLINICAL AND ENDOSCOPIC OUTCOMES IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 9.2 YEARS OF SAFETY DATA FROM THE GLOBAL CLINICAL PROGRAMME
TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 9.2 YEARS OF SAFETY DATA FROM THE GLOBAL CLINICAL PROGRAMME

EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION AND MAINTENANCE THERAPY FOR CROHN’S DISEASE: RESULTS FROM THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DIVERSITY1 STUDY
EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION AND MAINTENANCE THERAPY FOR CROHN’S DISEASE: RESULTS FROM THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DIVERSITY1 STUDY

Item 1 - 10 / 10
1